Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 20/20 | 0.81 |
| ▸ | HTR2A | P28223 | 9/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042859 | 0.89 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| SCHEMBL13220645 | 0.88 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7341669 | 0.87 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL4413286 | 0.87 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| SCHEMBL1405951 | 0.87 | HTR4 (0.98) | HTR4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL1405944 | 0.86 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| SCHEMBL1405907 | 0.84 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| Oxalic Acid SCHEMBL1405809 | 0.82 | HTR4 (1.00) | HTR4HTR2AKCNH2 | |
| Oxalic Acid SCHEMBL7344927 | 0.81 | HTR4 (0.85) | HTR4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7344684 | 0.80 | HTR4 (1.00) | HTR4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207776-B9 | DRUG ACTIVE IN NEUROPATHIC PAIN | ACRAF (IT) | 2016-12-21 | — | — | EP | disclosed |
| EP-2207776-B1 | DRUG ACTIVE IN NEUROPATHIC PAIN | ACRAF (IT) | 2016-08-17 | — | — | EP | disclosed |
| US-8455519-B2 | Drug active in neuropathic pain | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-06-04 | — | — | US | disclosed |
| US-20100215742-A1 | DRUG ACTIVE IN NEUROPATHIC PAIN | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-08-26 | — | — | US | disclosed |
| EP-2207776-A1 | DRUG ACTIVE IN NEUROPATHIC PAIN | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009062883-A1 | DRUG ACTIVE IN NEUROPATHIC PAIN | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215742-A1 | DRUG ACTIVE IN NEUROPATHIC PAIN | SCN1A, P2RX3, SCN3A | HTR4 3321/4885HTR2A 4250/4885KCNH2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.